Jyong Biotech Ltd. Company Profile
NASDAQ: MENSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jyong Biotech at a glance
Jyong Biotech Ltd. (NASDAQ: MENS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New Taipei City, Taiwan. Jyong Biotech is led by Ms. Fu-Feng Kuo and employs about 27 people. The company's shares have traded publicly since 2025.
At a market capitalization of $159.7 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001954488, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Jyong Biotech do?
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Business description based on the company's public filings.
Company information
- Legal name
- Jyong Biotech Ltd.
- Ticker
- NASDAQ: MENS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Fu-Feng Kuo
- Employees
- 27
- Headquarters
- No. 95, Xintai 5th Road, New Taipei City, Taiwan
- Phone
- 886 2 2732 5205
- Website
- jyongbio.com
- IPO year
- 2025
- Market cap
- $159.66M
- SEC CIK
- 0001954488
Companies similar to Jyong Biotech
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MSLESatellos Bioscience Inc. | 7.49 | +1.97% | $158.91M | vs MENS |
| NKTXNkarta Inc. | 2.25 | +1.35% | $161.16M | vs MENS |
| NBPNovaBridge Biosciences ADR | 1.40 | +1.82% | $161.82M | vs MENS |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs MENS |
| ORGOOrganogenesis Holdings Inc. Class A | 1.29 | +0.78% | $165.99M | vs MENS |
| ANTXAN2 Therapeutics Inc. | 4.40 | -5.98% | $166.04M | vs MENS |
| NERVMinerva Neurosciences Inc | 3.18 | -1.24% | $151.84M | vs MENS |
| TLSATiziana Life Sciences Ltd. | 1.19 | +5.31% | $151.44M | vs MENS |